Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
1 report, 1 independent
Updated Jun 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Regeneron conducted the clinical trial for a study related to co-developing new therapies.Sub-event
Intellia and Regeneron are partnering to co-develop therapies, with FDA approval being the next step.1 source
Keep exploring
The entities involved
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA
Related events
- Intellia Therapeutics announced it will present at a conference on September 4, 2026.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.